Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
367
Views
39
CrossRef citations to date
0
Altmetric
Reviews

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation

D Sangiolo Institute for Cancer Research and Treatment (IRCC), Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo (TO), Italy +39-011-9933-503; +39-011-9933-524; [email protected]; Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo (TO), Italy
,
G Mesiano Institute for Cancer Research and Treatment (IRCC), Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo (TO), Italy +39-011-9933-503; +39-011-9933-524; [email protected]
,
F Carnevale-Schianca Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo (TO), Italy
,
W Piacibello Institute for Cancer Research and Treatment (IRCC), Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo (TO), Italy +39-011-9933-503; +39-011-9933-524; [email protected]
,
M Aglietta Institute for Cancer Research and Treatment (IRCC), Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo (TO), Italy +39-011-9933-503; +39-011-9933-524; [email protected]; Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo (TO), Italy
&
A Cignetti Institute for Cancer Research and Treatment, Laboratory of Cancer Immunology, Candiolo (TO), Italy
Pages 831-840 | Published online: 25 May 2009

Bibliography

  • Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343(11):750-8
  • Carnevale-Schianca F, Cignetti A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T-cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006;107(9):3795-803
  • Aglietta M, Barkholt L, Schianca FC, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European Group for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant 2009;15(3):326-35
  • Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15(2):433-44
  • Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103(3):790-5
  • van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37(12):1135-41
  • Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174(1):139-49
  • Baker J, Verneris MR, Ito M, et al. Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 2001;97(10):2923-31
  • Eberl G, Lees R, Smiley ST, et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999;162(11):6410-9
  • Lu PH, Negrin RS. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153(4):1687-96
  • Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994;87(3):453-8
  • Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008;20(7):841-8
  • Linn YC, Lau SK, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009;126(3):423-35
  • Ortaldo JR, Winkler-Pickett RT, Yagita H, Young HA. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991;136(2):486-95
  • Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987;138(8):2728-33
  • Anderson PM, Bach FH, Ochoa AC. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother 1988;27(1):82-8
  • Kimoto Y. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Hum Cell 1992;5(3):226-35
  • Ueda M, Joshi ID, Dan M, et al. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993;56(2):351-6
  • Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-γ of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995;86(2):646-50
  • Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J Exp Med 1996;183(1):147-57
  • Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 2001;49(12):629-40
  • Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998;47(4):221-6
  • Finke S, Trojaneck B, Lefterova P, et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Therapy 1998;5(1):31-9
  • Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001;7(4):216-22
  • Introna M, Franceschetti M, Ciocca A, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006;38(9):621-7
  • Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21(13):1673-9
  • Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995;86(9):3493-9
  • Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173(4):1017-20
  • Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17(1):19-29
  • Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunol 2000;1(2):119-26
  • Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14(2):123-33
  • Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004;103(8):3065-72
  • Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3+ CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92(9):3318-27
  • Verneris MR, Ito M, Baker J, et al. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7(10):532-42
  • Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008;112(6):2563-74
  • Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a Phase I study. Haematologica 2007;92(7):952-9
  • Laport G, Sheehan K, Lowsky R, et al. Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation. Blood 2006;108(11):Abstract 412
  • Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Bri J Cancer 1999;81(6):1009-16
  • Leemhuis T, Wells S, Scheffold C, et al. A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11(3):181-7
  • Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009 [Epub ahead of print; doi:10.1002/hon.886]
  • Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009;41(1):36-41
  • Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28(6B):3997-4002
  • Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006;26(3B):2237-42
  • Yang YG, Dey BR, Sergio JJ, et al. Donor-derived interferon γ is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998;102(12):2126-35
  • Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998;101(9):1835-42
  • Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 1992;148(9):2953-60
  • Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31(1):63-71
  • Shi M, Zhang B, Tang ZR. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10(8):1146-51

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.